Compare KRRO & CHPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KRRO | CHPT |
|---|---|---|
| Founded | 2014 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Specialties |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 150.0M | 168.2M |
| IPO Year | 2019 | 2019 |
| Metric | KRRO | CHPT |
|---|---|---|
| Price | $9.17 | $6.18 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 12 | 9 |
| Target Price | ★ $34.80 | $9.25 |
| AVG Volume (30 Days) | 75.1K | ★ 429.3K |
| Earning Date | 05-13-2026 | 06-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $6,392,000.00 | ★ $411,224,000.00 |
| Revenue This Year | N/A | $4.18 |
| Revenue Next Year | N/A | $16.63 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 181.46 | N/A |
| 52 Week Low | $5.20 | $0.58 |
| 52 Week High | $55.89 | $12.62 |
| Indicator | KRRO | CHPT |
|---|---|---|
| Relative Strength Index (RSI) | 27.11 | 47.39 |
| Support Level | $8.01 | $6.03 |
| Resistance Level | $14.52 | $6.73 |
| Average True Range (ATR) | 0.89 | 0.38 |
| MACD | -0.40 | -0.05 |
| Stochastic Oscillator | 0.00 | 16.54 |
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability. The company operates and manages its business as one reportable segment and one operating segment, which is the business of discovering, developing and commercializing therapies derived from or incorporating its RNA-editing technology.
ChargePoint Holdings Inc designs, develops, and markets networked electric vehicle charging system infrastructure and cloud-based services that enable charging systems owners, charge point operators, to manage their Networked Charging Systems, and to enable drivers to locate, reserve and authenticate Networked Charging Systems and to transact EV charging sessions on those systems. The company's hardware product lineup includes solutions across home, commercial, and fast-charging applications. The company derives the majority of its revenue from the United States.